Imipramine Pamoate | CAS# 10075-24-8 | Tricyclic Antidepressant

MedKoo Cat#: 574748 | Name: Imipramine Pamoate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Imipramine Pamoate is a tricyclic antidepressant.

Chemical Structure

Imipramine Pamoate

CAS#10075-24-8

Theoretical Analysis

MedKoo Cat#: 574748

Name: Imipramine Pamoate

CAS#: 10075-24-8

Chemical Formula: C61H64N4O6

Exact Mass:

Molecular Weight: 949.21

Elemental Analysis: C, 77.19; H, 6.80; N, 5.90; O, 10.11

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Imipramine Pamoate

IUPAC/Chemical Name

3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hemi(4,4'-methylenebis(3-hydroxy-2-naphthoate))

InChi Key

BPQZYOJIXDMZSX-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H16O6.2C19H24N2/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*3-6,8-11H,7,12-15H2,1-2H3

SMILES Code

CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Imipramine pamoate is a potent anti-depressant compound.

In vitro activity:

To confirm these results in a more physiologically relevant model, this study tested the effect of imipramine treatment in 4T1 isograft model, which closely mimics the aggressive human TNBCs. After 4T1 isograft tumors reached 100 mm3, BALB/c mice were treated with vehicle or 32 mg/kg imipramine for three weeks. Imipramine-treated mice had significantly reduced tumor volumes compared to vehicle-treated 4T1-derived tumors (Supplementary Fig. 1e). Reference: Cancer Lett. 2022 Aug 1;540:215717. https://pubmed.ncbi.nlm.nih.gov/35568265/

In vivo activity:

Results show that the gene expression of COX-2, iNOS, and NF-κB was higher in imipramine-treated mice compared with controls (1.5, 1.8, and 1.2 times higher, respectively; Figure 9b,c, respectively). By contrast, the gene expression of IκBα in imipramine-treated mice was 18% lower than that in controls (Figure 9d). These results indicate that imipramine increased the risk of DR (diabetic retinopathy) by elevating inflammation and glucose uptake. Reference: Vet Sci. 2021 Sep 9;8(9):189. https://pubmed.ncbi.nlm.nih.gov/34564583/

Preparing Stock Solutions

The following data is based on the product molecular weight 949.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N, Viswanadhapalli S, Chen Y, Jatoi I, Brenner A, Rao MK, Vadlamudi R, Kaklamani V. The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. Cancer Lett. 2022 Aug 1;540:215717. doi: 10.1016/j.canlet.2022.215717. Epub 2022 May 12. PMID: 35568265. 2. Wang Y, Wang X, Wang X, Wu D, Qi J, Zhang Y, Wang K, Zhou D, Meng QM, Nie E, Wang Q, Yu RT, Zhou XP. Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide. J Cell Mol Med. 2021 Oct;25(19):9350-9363. doi: 10.1111/jcmm.16874. Epub 2021 Sep 1. PMID: 34469035; PMCID: PMC8500960. 3. Yueh PF, Lee YH, Chiang IT, Chen WT, Lan KL, Chen CH, Hsu FT. Suppression of EGFR/PKC-δ/NF-κB Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer. Front Oncol. 2021 Oct 26;11:735183. doi: 10.3389/fonc.2021.735183. PMID: 34765548; PMCID: PMC8576332. 4. Chang GR, Hou PH, Wang CM, Lin JW, Lin WL, Lin TC, Liao HJ, Chan CH, Wang YC. Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice. Vet Sci. 2021 Sep 9;8(9):189. doi: 10.3390/vetsci8090189. PMID: 34564583; PMCID: PMC8473438.

In vitro protocol:

In vivo protocol:

1. Yueh PF, Lee YH, Chiang IT, Chen WT, Lan KL, Chen CH, Hsu FT. Suppression of EGFR/PKC-δ/NF-κB Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer. Front Oncol. 2021 Oct 26;11:735183. doi: 10.3389/fonc.2021.735183. PMID: 34765548; PMCID: PMC8576332. 2. Chang GR, Hou PH, Wang CM, Lin JW, Lin WL, Lin TC, Liao HJ, Chan CH, Wang YC. Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice. Vet Sci. 2021 Sep 9;8(9):189. doi: 10.3390/vetsci8090189. PMID: 34564583; PMCID: PMC8473438.

1. Huang Y, Xu D, Xiang H, Yan S, Sun F, Wei Z. Rapid antidepressant actions of imipramine potentiated by zinc through PKA-dependented regulation of mTOR and CREB signaling. Biochem Biophys Res Commun. 2019;518(2):337-343. doi:10.1016/j.bbrc.2019.08.059 2. Ravanshad Y, Azarfar A, Esmaeeli M, Mostafavian Z, Zahabi E, Ravanshad S. Effect of Low Dose Imipramine in Patients with Nocturnal Enuresis, A Randomized Clinical Trial. Iran J Kidney Dis. 2019;13(4):257-261.